EGFR mutation testing practices within the Asia pacific region: Results of a multicenter diagnostic survey

Yasushi Yatabe, Keith M. Kerr, Ahmad Utomo, Pathmanathan Rajadurai, Van Khanh Tran, Xiang Du, Teh Ying Chou, Ma Luisa D Enriquez, Geon Kook Lee, Jabed Iqbal, Shanop Shuangshoti, Jin Haeng Chung, Koichi Hagiwara, Zhiyong Liang, Nicola Normanno, Keunchil Park, Shinichi Toyooka, Chun Ming Tsai, Paul Waring, Li ZhangRose Mccormack, Marianne Ratcliffe, Yohji Itoh, Masatoshi Sugeno, Tony Mok

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Introduction: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. Methods: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. Results: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%-32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme. Conclusions: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.

Original languageEnglish
Pages (from-to)438-445
Number of pages8
JournalJournal of Thoracic Oncology
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 30 2015

Fingerprint

Epidermal Growth Factor Receptor
Mutation
Non-Small Cell Lung Carcinoma
Cell Biology
Surveys and Questionnaires
DNA Sequence Analysis
Protein-Tyrosine Kinases
Confidence Intervals
Pathology
Biopsy

Keywords

  • EGFR mutation
  • Multicenter
  • Non-small-cell lung cancer
  • Survey
  • Testing

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

EGFR mutation testing practices within the Asia pacific region : Results of a multicenter diagnostic survey. / Yatabe, Yasushi; Kerr, Keith M.; Utomo, Ahmad; Rajadurai, Pathmanathan; Tran, Van Khanh; Du, Xiang; Chou, Teh Ying; Enriquez, Ma Luisa D; Lee, Geon Kook; Iqbal, Jabed; Shuangshoti, Shanop; Chung, Jin Haeng; Hagiwara, Koichi; Liang, Zhiyong; Normanno, Nicola; Park, Keunchil; Toyooka, Shinichi; Tsai, Chun Ming; Waring, Paul; Zhang, Li; Mccormack, Rose; Ratcliffe, Marianne; Itoh, Yohji; Sugeno, Masatoshi; Mok, Tony.

In: Journal of Thoracic Oncology, Vol. 10, No. 3, 30.03.2015, p. 438-445.

Research output: Contribution to journalArticle

Yatabe, Y, Kerr, KM, Utomo, A, Rajadurai, P, Tran, VK, Du, X, Chou, TY, Enriquez, MLD, Lee, GK, Iqbal, J, Shuangshoti, S, Chung, JH, Hagiwara, K, Liang, Z, Normanno, N, Park, K, Toyooka, S, Tsai, CM, Waring, P, Zhang, L, Mccormack, R, Ratcliffe, M, Itoh, Y, Sugeno, M & Mok, T 2015, 'EGFR mutation testing practices within the Asia pacific region: Results of a multicenter diagnostic survey', Journal of Thoracic Oncology, vol. 10, no. 3, pp. 438-445. https://doi.org/10.1097/JTO.0000000000000422
Yatabe, Yasushi ; Kerr, Keith M. ; Utomo, Ahmad ; Rajadurai, Pathmanathan ; Tran, Van Khanh ; Du, Xiang ; Chou, Teh Ying ; Enriquez, Ma Luisa D ; Lee, Geon Kook ; Iqbal, Jabed ; Shuangshoti, Shanop ; Chung, Jin Haeng ; Hagiwara, Koichi ; Liang, Zhiyong ; Normanno, Nicola ; Park, Keunchil ; Toyooka, Shinichi ; Tsai, Chun Ming ; Waring, Paul ; Zhang, Li ; Mccormack, Rose ; Ratcliffe, Marianne ; Itoh, Yohji ; Sugeno, Masatoshi ; Mok, Tony. / EGFR mutation testing practices within the Asia pacific region : Results of a multicenter diagnostic survey. In: Journal of Thoracic Oncology. 2015 ; Vol. 10, No. 3. pp. 438-445.
@article{0fe0302b696a46bf987a2db587ee71fd,
title = "EGFR mutation testing practices within the Asia pacific region: Results of a multicenter diagnostic survey",
abstract = "Introduction: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. Methods: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. Results: Of the 22,193 NSCLC patient records surveyed, 31.8{\%} (95{\%} confidence interval: 31.2{\%}-32.5{\%}) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6{\%} among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4{\%}). DNA sequencing was the most commonly used testing method accounting for 40{\%} and 32.5{\%} of tissue and cytology samples, respectively. A pathology report was available only to 60.0{\%} of the sites, and 47.5{\%} were not members of a Quality Assurance Scheme. Conclusions: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.",
keywords = "EGFR mutation, Multicenter, Non-small-cell lung cancer, Survey, Testing",
author = "Yasushi Yatabe and Kerr, {Keith M.} and Ahmad Utomo and Pathmanathan Rajadurai and Tran, {Van Khanh} and Xiang Du and Chou, {Teh Ying} and Enriquez, {Ma Luisa D} and Lee, {Geon Kook} and Jabed Iqbal and Shanop Shuangshoti and Chung, {Jin Haeng} and Koichi Hagiwara and Zhiyong Liang and Nicola Normanno and Keunchil Park and Shinichi Toyooka and Tsai, {Chun Ming} and Paul Waring and Li Zhang and Rose Mccormack and Marianne Ratcliffe and Yohji Itoh and Masatoshi Sugeno and Tony Mok",
year = "2015",
month = "3",
day = "30",
doi = "10.1097/JTO.0000000000000422",
language = "English",
volume = "10",
pages = "438--445",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - EGFR mutation testing practices within the Asia pacific region

T2 - Results of a multicenter diagnostic survey

AU - Yatabe, Yasushi

AU - Kerr, Keith M.

AU - Utomo, Ahmad

AU - Rajadurai, Pathmanathan

AU - Tran, Van Khanh

AU - Du, Xiang

AU - Chou, Teh Ying

AU - Enriquez, Ma Luisa D

AU - Lee, Geon Kook

AU - Iqbal, Jabed

AU - Shuangshoti, Shanop

AU - Chung, Jin Haeng

AU - Hagiwara, Koichi

AU - Liang, Zhiyong

AU - Normanno, Nicola

AU - Park, Keunchil

AU - Toyooka, Shinichi

AU - Tsai, Chun Ming

AU - Waring, Paul

AU - Zhang, Li

AU - Mccormack, Rose

AU - Ratcliffe, Marianne

AU - Itoh, Yohji

AU - Sugeno, Masatoshi

AU - Mok, Tony

PY - 2015/3/30

Y1 - 2015/3/30

N2 - Introduction: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. Methods: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. Results: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%-32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme. Conclusions: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.

AB - Introduction: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. Methods: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. Results: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%-32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme. Conclusions: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.

KW - EGFR mutation

KW - Multicenter

KW - Non-small-cell lung cancer

KW - Survey

KW - Testing

UR - http://www.scopus.com/inward/record.url?scp=84931571793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931571793&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000422

DO - 10.1097/JTO.0000000000000422

M3 - Article

C2 - 25376513

AN - SCOPUS:84931571793

VL - 10

SP - 438

EP - 445

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -